Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Hormones

Volumn 15, Issue 1, 2016, Pages 8-14

  Achimastos, Apostolos ^a   Alexandrides, Theodoros ^b   Alexopoulos, Dimitrios ^b   Athyros, Vasilios ^c   Bargiota, Alexandra ^d   Bilianou, Eleni ^e   Chrysochoou, Christina ^f   Drogari, Evridiki ^a   Elisaf, Moses ^g   Ganotakis, Emanouel ^h   Goudevenos, Ioannis ^g   Ioannidis, Ioannis ⁱ   Kolovou, Genovefa ^j   Kotsis, Vasilios ^c   Lekakis, Ioannis ^a   Liberopoulos, Evangelos ^g   Melidonis, Andreas ^e   Nikolaou, Vasilios ^k   Ntaios, George ^d   Papanas, Nikolaos ^l   Pappas, Stavros ^m   Pitsavos, Christos ^a   Rallidis, Loukianos ⁿ   Richter, Dimitrios ^o   Skoumas, Ioannis ^f   Tentolouris, Nicolaos ^a   Tousoulis, Dimitrios ^a   Tselepis, Alexandros ^g   Tsioufis, Konstantinos ^a   Tziakas, Dimitrios ^l   Tziomalos, Konstantinos ^c   Vardas, Panagiotis ^h   Vlachopoulo, Charalabos ^a   Vlahakos, Dimitrios ^a   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

^e TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^f HIPPOKRATION HOSPITAL   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h UNIVERSITY OF CRETE   (Greece)

ⁱ General Hospital of Nea Ionia Konstantopouleio Patission   (Greece)

^j Past President of the Hellenic Atherosclerosis Society   (Greece)

^k Korgialenio Benakio HRC Hospital   (Greece)

^l DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^m President of the Institute for the Study   (Greece)

ⁿ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^o Athens Euroclinic   (Greece)

more..

Author keywords

Cardiovascular disease; Diabetes; Ezetimibe; Familial hypercholesterolemia; High risk; LDL cholesterol; PCSK9; Statin intolerance; Statins

Indexed keywords

ALIROCUMAB; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSENSUS; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERANCE; DRUG USE; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; ARTICLE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DRUG INDUSTRY; DRUG TOLERABILITY; MORBIDITY; MORTALITY; RISK FACTOR; SCORING SYSTEM;

HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; PROPROTEIN CONVERTASE 9;

EID: 84964296736     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1659     Document Type: Editorial

References (38)

1. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ, 2008 Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49: 394-398.
2. Elisaf M, Liberopoulos E, Pitsavos C, et al, 2014 Updated guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia-2014. Hellenic J Atheroscler 5: 151-163 [in Greek]
3. European Association for Cardiovascular Prevention & Rehabilitaiton,Reiner Z, Catapano AL, De Backer G, et al, 2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769-1818.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al, 2014 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129: Supple 2: 1-45.
5. Anderson TJ, Gregoire J, Hegele RA, et al, 2013 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29: 151-167.
6. Grundy SM, Arai H, Barter P, et al, 2014 An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 8: 29-60.
7. American Diabetes Association, 2015 Standards of Medical Care in Diabetes - 2015. Diabetes Care 38: Suppl 1: 49-57.
8. Navarese EP, Kolodziejczak M, Schulze V, et al, 2015 Effects of Proprotein Convertase Subtilisin/ KexinType 9. Antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 163: 40-51
9. Zhang XL, et al, 2015 Safety and efficacy of anti-PCSK9 antibodies: a metaanalysis of 25 randomized, controlled trials. BMC Med 13: 123.
10. Lipinski MJ, Benedetto U, Escarcega RO, et al, 2016 The impact of proprotein convertase subtilisinkexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 37: 536-545
11. Jacobson TA, Maki KC, Orringer CE, et al, 2015 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 9: Suppl 1: 1-122
12. Robinson JG, Nedergaard BS, Rogers WJ, et al, 2014 Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311: 1870-1882.
13. Stein EA, Mellis S, Yancopoulos GD, et al, 2012 Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366: 1108-1118.
14. Blom DJ, Hala T, Bolognese M, et al, 2014 A 52-week placebo-controlled trial of evolocumab in hyperlipid-emia. N Engl J Med 370: 1809-1819.
15. Stroes E, Colquhoun D, Sullivan D, et al, 2014 Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63: 2541-2548.
16. Koren MJ, Lundqvist P, Bolognese M, et al, 2014 Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63: 2531-2540.
17. Koren MJ, Giugliano RP, Raal FJ, et al, 2014 Efficacy and safety of longer term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 129: 234-243.
18. Raal FJ, Honarpour N, Blom DJ, et al, 2015 Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385: 341-350.
19. Sabatine MS, Giugliano RP, Wiviott SD et al, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators 2015 Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500-1509
20. Robinson JG, Farnier M, Krempf M, et al, ODYSSEY LONG TERM Investigators, 2015 Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489-1499.
21. Stroes ES, Thompson PD, Corsini A, et al, European Atherosclerosis Society Consensus Panel, 2015 Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36: 1012-1022.
22. Guyton JR, Bays HE, Grundy SM, Jacobson TA, 2014 The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8: Suppl: 72-81.
23. Rosenson RS, Baker SK, Jacobson TA, et al, 2014 The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8: Suppl: 58-71.
24. Mancini GB, Tashakkor AY, Baker S, et al, 2013 Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 29: 1553-1568.
25. Banach M, Rizzo M, Toth PP, et al, 2015 Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11: 1-23.
26. Raal FJ, Stein EA, Dufour R et al, RUTHERFORD-2 Investigators, 2015 PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385: 331-340
27. Nordestgaard BG, Chapman MJ, Humphries SE, et al, European Atherosclerosis Society Consensus Panel, 2013 Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34: 3478-3490.
28. Roth EM, Taskinen MR, Ginsberg HN, et al, 2014 Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 176: 55-61.
29. Boekholdt SM, Hovingh GK, Mora S et al, 2014 Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64: 485-494.
30. Everett BM, Smith RJ, Hiatt WR, 2015 Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs. N Engl J Med 373: 1588-1591.
31. Giugliano RP, Sabatine MS, 2015 Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 65: 2638-2651.
32. Kastelein JJ, Ginsberg HN, Langslet G, et al, 2015 ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36: 2996-3003.
33. Bays H, Gaudet D, Weiss R, et al, 2015 Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 100: 3140-3148.
34. Kereiakes DJ, Robinson JG, Cannon CP, et al, 2015 Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 169: 906-915.e13.
35. Verbeek R, Stoekenbroek RM, Hovingh GK, 2015 PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol 7 63(Pt A): 38-44.
36. Cannon CP, Cariou B, Blom D et al, ODYSSEY COMBO II Investigators, 2015 Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 36: 1186-1194.
37. Schwartz GG, Bessac L, Berdan LG, et al, 2014 Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168: 682-689.
38. Panagiotakos DB, Fitzgerald AP, Pitsavos C, et al, 2007 Statistical modeling of 10-year fatal cardiovascular disease risk in Greece: the Hellenic SCORE (a calibration of the ESC Score project). Hellenic J Cardiol 48: 55-63.